# Escalon Medical Corp. (ESMC)

> Source: Nexqual · https://nexqual.com/ESMC · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Escalon Medical Corp. (ESMC), nexqual.com/ESMC" · informational, not investment advice.

**Price:** USD 0.17 (+0.00% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 0.17 · day 0.18–0.18 · 52w 0.14–0.29 · market cap $1.3M · OQB

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $12.7M, net income $4.0M (31.5% margin), free cash flow -$407K (SEC filings).
- Valuation: P/E 0.3x (avg 22.0x at the last 2 fiscal year-ends).
- Analysts: None.
- Total return with dividends: 1Y +6.3% vs S&P 500 +13.4%; 5Y -15.0% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $10.7M | $12.2M | $12.0M | $12.0M | $12.7M | $12.7M |
| Gross profit | $4.6M | $5.5M | $5.1M | $5.5M | $5.6M | — |
| Operating income | -$470K | $479K | -$104K | $133K | $45K | $45K |
| Net income | $18K | $457K | -$125K | $106K | $4.0M | $4.0M |
| EPS (diluted) | $0.00 | $0.03 | -$0.02 | $0.00 | $0.27 | — |
| Free cash flow | -$1.0M | $318K | -$643K | $377K | -$407K | -$407K |
| Gross margin | 43.0% | 45.0% | 43.0% | 45.7% | 43.7% | — |
| Operating margin | -4.4% | 3.9% | -0.9% | 1.1% | 0.4% | 0.4% |
| Net margin | 0.2% | 3.8% | -1.0% | 0.9% | 31.5% | 31.5% |
| Revenue growth | +2.2% | +13.8% | -1.6% | +0.5% | +5.7% | — |
| Cash + short-term investments | $594K | $890K | $209K | $546K | $3.1M | — |
Fiscal years end Jun. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 0.3x · P/S 0.1x · P/B 0.2x · FCF yield -32.29% · Earnings yield 318.31%
P/E at fiscal year-ends: Jun 2026 0.7x, Jun 2025 43.2x.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +6.3% | -15.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +6.3% | -3.2% |
| Volatility (annualized) | 102.9% | 119.8% |
| Max drawdown | -44.0% (Feb 2026→Apr 2026) | -76.2% (Nov 2021→Jan 2023) |

## Peers (Medical Devices)
ATEC (Alphatec Holdings, Inc.) USD 11.11 -2.20% · BFLY (Butterfly Network, Inc.) USD 6.76 -0.73% · ESTA (Establishment Labs Holdings Inc) USD 63.8 +0.44% · INSP (Inspire Medical Systems, Inc.) USD 71.11 -2.13% · ALMR (Alamar Biosciences, Inc.) USD 30.69 +3.26% · AXGN (AxoGen, Inc.) USD 38.06 +3.76%

## More
Full page: https://nexqual.com/ESMC · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Product | $3.7M | 94.8% | +49.6% |
| Service | $202,111 | 5.2% | +62.2% |
| Total revenue | $3.9M | 100% | — |

## Customer concentration

Period ended 2026-06-30: 12% of revenue from unnamed direct customers (10-K, filed 2026-10-13).

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2011-06-30) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |